As a result dividend cover has gone from 1.4 times earnings in 1991 to just over three times - which has become a minimum level of cover the company considers acceptable.
That is at a time when many other healthcare-related companies have been reducing their cover as they transform themselves into yield stocks - cover at Glaxo, the drug sector giant, now stands at 1.8 times earnings but yields more than 5 per cent, compared with less than 2 per cent for Amersham, for instance.
The reason is simple: unlike the big drug groups, Amersham's niche products are relatively safe from the winds of change blowing through the industry. It has no need to bribe its shareholders to ensure that their nerves hold steady.
That means that for investors the only thing that matters is whether Amersham can make better use of its money than they can.
So far the group has to be given the benefit of the doubt. Earnings have almost tripled over the past four years, and there seems little doubt but that 1994's pre-tax results will be bettered next year - analysts expect this year's pounds 43.5m, up from pounds 26.3m in 1993, to rise to pounds 52m next year.
To date, Amersham has invested well in research and development and sensible acquisitions, and its products have tantalising potential.
Amersham now enters an even more testing phase. Until now it has been paying down debt; from here on in the cash will begin to build in its balance sheet. The more successful Amersham becomes, the greater the task it sets itself when it comes to using that money wisely.
At a premium of 25 per cent to the market the shares sound expensive. But the group is one of the few growth prospects in the sector.
(Graph omitted)Reuse content